Vaxart Management
Management criteria checks 2/4
Vaxart's CEO is Steven Lo, appointed in Mar 2024, has a tenure of 1.17 years. total yearly compensation is $2.21M, comprised of 21.4% salary and 78.6% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth €13.44K. The average tenure of the management team and the board of directors is 3.3 years and 3.8 years respectively.
Key information
Steven Lo
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 21.4% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.02% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$2m | US$474k | -US$67m |
Compensation vs Market: Steven's total compensation ($USD2.21M) is above average for companies of similar size in the German market ($USD499.53K).
Compensation vs Earnings: Insufficient data to compare Steven's compensation with company performance.
CEO
Steven Lo (57 yo)
1.2yrs
Tenure
US$2,213,697
Compensation
Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. From October 2019 to August 2022, Mr. Lo was the President, Chief Executive Officer and member of the board of direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.2yrs | US$2.21m | 0.018% € 13.4k | |
| Senior VP & Chief Scientific Officer | 15.3yrs | US$1.16m | 0.12% € 90.6k | |
| Chief Medical Officer | 3.8yrs | US$1.21m | 0.094% € 72.1k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 2.4yrs | no data | 0.047% € 35.8k | |
| Chief Technology Officer | 2.8yrs | no data | no data | |
| Senior VP & General Counsel | 3.3yrs | no data | 0.077% € 58.8k | |
| Senior Vice President of Human Resources | less than a year | no data | no data | |
| Senior Vice President of Clinical Development & Project Management | 5.2yrs | no data | no data | |
| Senior Vice President of Quality | 4.3yrs | no data | no data |
3.3yrs
Average Tenure
56.5yo
Average Age
Experienced Management: NB11's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.2yrs | US$2.21m | 0.018% € 13.4k | |
| Member of Scientific & Clinical Advisory Board | 3.8yrs | no data | no data | |
| Independent Director | 2.8yrs | US$143.78k | 0.0086% € 6.6k | |
| Independent Chairman of the Board | 7.3yrs | US$858.00k | 0.29% € 224.6k | |
| Member of Scientific & Clinical Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 3.8yrs | no data | no data | |
| Independent Director | 4.1yrs | US$146.98k | 0.0065% € 4.9k | |
| Member of Scientific & Clinical Advisory Board | 3.8yrs | no data | no data | |
| Independent Director | 2.8yrs | US$94.76k | 0.025% € 19.2k | |
| Member of Scientific & Clinical Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
70yo
Average Age
Experienced Board: NB11's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 15:25 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxart, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Roger Song | Jefferies LLC |
| Cheng Li | Oppenheimer & Co. Inc. |